Nadifloxacin
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | topical (epicutaneous) |
ATC code | |
Identifiers | |
| |
JSmol) | |
Chirality | Racemic mixture |
Melting point | 245 to 247 °C (473 to 477 °F) (dec.) |
| |
| |
(what is this?) (verify) |
Nadifloxacin (
Pharmacology
Antibacterial spectrum
In vitro studies of nadifloxacin showed potent and broad-spectrum antibacterial activity against aerobic
Mechanism of action
Nadifloxacin
Pharmacokinetics
Following a single topical application of 10 g nadifloxacin 1% cream to normal human back skin, the highest plasma concentration was determined to be 107 ng/mL with an elimination half-life of 19.4 hours. Approximately 0.09% of the administered dose was excreted in the urine over 48 hours post- dosing. The plasma concentration reached a steady state on Day 5 of repeated administration study when nadifloxacin 1% cream was applied at 5 g twice daily to normal healthy individuals for a period of 7 days. The plasma concentration reached a peak of 4.1 ng/ml at 8 hours post-final dosing with an elimination half-life of 23.2 hours. The urinary excretion rate reached 0.16% on Day 7.
Clinical use
In some European countries, the drug has been approved for the treatment of acne vulgaris.[5] In a 2013 multicenter, randomized clinical study with a total of 184 Japanese patients with moderate to severe acne, adapalene 0.1% gel plus nadifloxacin 1% cream (combination therapy) showed a significant efficacy in decrement of inflammatory papulopustular lesions.[6] In patients with skin lesions, topical application of nadifloxacin can result in plasma concentrations of 1 to 3 ng/ml. Consequently, some authors argued that it should not be used to treat relatively harmless diseases like acne vulgaris, risking the development of quinolone
Adverse effects
During the treatment some patients may develop some adverse effects predominantly of the skin and subcutaneous tissue: burning and